Nexalin Technology, Inc.
NXL Nasdaq
SEC CIK 1527352
Follow Nexalin Technology
Weekly email: filings, results
Revenue, last quarter
$78.3K
+331.4% vs same quarter last year
Net income
−$2.7M
−16.9% vs same quarter last year
EPS, diluted
−$3.43
+10.7% vs same quarter last year
Operating cash flow
−$1.6M
−8.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $301.6K | −$8.2M |
| FY24 | $168.7K | −$7.6M |
| FY23 | $110.7K | −$4.6M |
| FY22 | $1.3M | −$1.7M |
| FY21 | $144.1K | −$6.1M |
| FY20 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 79.7% | −2781.7% | −2725.8% |
| FY24 | 78.3% | −4596.1% | −4508.7% |
| FY23 | 76.8% | −5143.5% | −4197.6% |
| FY22 | 72.5% | −138.7% | −128.5% |
| FY21 | 85.1% | −4177.7% | −4218.9% |
| FY20 | - | - | - |
- Nexalin Technology
- Healthcare median
Show the numbers
| Year | Nexalin Technology | Healthcare median |
|---|---|---|
| FY25 | −2725.8% | −30.6% |
| FY24 | −4508.7% | −47% |
| FY23 | −4197.6% | −58% |
| FY22 | −128.5% | −80.4% |
| FY21 | −4218.9% | −71.8% |
| FY20 | - | −62.2% |